



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignita 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/462,472	01/14/2000	HIROSHI MATSUI	0010-1075-0-	5130
22850	7590 05/06/2003			
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			EXAMINER	
	40 DUKE STREET LEXANDRIA, VA 22314		FRONDA, CHRISTIAN L	
			ART UNIT	PAPER NUMBER
			1652	97
			DATE MAILED: 05/06/2003	<i>(1)</i>

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. **09/462,472** 

Applicant(s)

Matsui et al.

Examiner

Christian L. Fronda

Art Unit 1652



	The MAILING DATE of this communication appears of	on the cover sheet with the correspondence address		
Period f	for Reply			
THEN	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. ions of time may be available under the provisions of 37 CFR 1.136 (a). In a	TO EXPIRE 3 MONTH(S) FROM  no event, however, may a reply be timely filed after SIX (6) MONTHS from the		
mailing - If the p - If NO p - Failure - Any rej	l date of this communication. period for reply specified above is less than thirty (30) days, a reply within th	ne statutory minimum of thirty (30) days will be considered timely.  Ind will expire SIX (6) MONTHS from the mailing date of this communication.  Indeed the second process of t		
Status				
1) 🗌	Responsive to communication(s) filed on			
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This act	ion is non-final.		
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under Ex pair	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.		
Disposit	tion of Claims			
4) 💢	Claim(s) <u>13-22, 25, and 27</u>	is/are pending in the application.		
4	a) Of the above, claim(s)	is/are withdrawn from consideration.		
5) 🗆	Claim(s)	is/are allowed.		
6) 💢	Claim(s) <u>13-22, 25, and 27</u>	is/are rejected.		
7) 🗆	Claim(s)	is/are objected to.		
8) 🗆	Claims	are subject to restriction and/or election requirement.		
Applica	tion Papers			
9) 🗆	The specification is objected to by the Examiner.			
10) The drawing(s) filed on is/are a) is/are a) accepted or b) objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.		
	If approved, corrected drawings are required in reply t	to this Office action.		
12)	The oath or declaration is objected to by the Exami	ner.		
Priority under 35 U.S.C. §§ 119 and 120				
13) 💢 Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) 🗴	☑ All b)□ Some* c)□ None of:			
•	1. 🕱 Certified copies of the priority documents have	e been received.		
,	2. $\square$ Certified copies of the priority documents have	e been received in Application No		
	application from the International Burea			
	ee the attached detailed Office action for a list of the			
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).				
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>				
Attachme		priority under 33 0.3.C. 33 120 and/or 121.		
	tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Peper No(s).		
2) No	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)		
3) 🔲 Info	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:		

Application/Control Number: 09/462,472 Page 2

Art Unit: 1652

### **DETAILED ACTION**

- 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants' submission filed on 3/12/2003 (Paper No. 19) has been entered.
- 2. Claims 13-22, 25, and 27 under consideration in this Office Action.

## Claim Objections

3. Claims 13-22 and 25 are objected to because of they recite non-elected subject matter. Applicants are required to cancel or amend the claims to recite the elected subject matter of phosphoglucose isomerase.

## Claim Rejections - 35 U.S.C. § 112, 2nd Paragraph

- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 5. Claims 14-22 and 25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 14 recites the limitation that expression of a gene encoding phosphoribosyl pyrohposphate amidotransferase or a phosphoribosyl pyrophosphate synthase is increased. There is insufficient antecedent basis for this limitation in the claim. Claims 17 and 20 which depend from claim 14 are also rejected because they do not correct the defect of claim 14.

Claim 15 recites the limitation that control of phosphoribosyl pyrohosphate amidotransferase or a phosphoribosyl pyrophosphate synthase is deregulated. There is insufficient antecedent basis for this limitation in the claim. Claims 18, 21, and 22 which depend from claim 15 are also rejected because they do not correct the defect of claim 15.

Art Unit: 1652

In claim 16, the phrase "control of the enzyme involved in the purine nucleoside biosynthesis is desensitized by desensitization of feedback inhibition" renders the claim vague and indefinite because the specific enzyme which is desensitized by desensitization of feedback inhibition is not known and recited in the claim. Furthermore, there is insufficient antecedent basis for this limitation in the claim. Claim 19 which depends from claim 16 is also rejected because the claim does not correct the defect of claim 16.

In claim 22, the phrase "control of the enzyme involved in the purine nucleoside biosynthesis is derepressed by inactivation of a purine repressor encoded by *purR*" renders the claim vague and indefinite because the specific enzyme which is derepressed is not known and recited in the claim. Furthermore, there is insufficient antecedent basis for this limitation in the claim.

Claim 25 recites the limitation that purine nucleoside incorporation is inhibited by blockage of a reaction catalyzed by nucleoside permease. There is insufficient antecedent basis for this limitation in the claim.

#### Conclusion

- 6. No claim is allowed.
- 7. Claim 27 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (703)305-1252. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. The fax phone number for this Group is (703)308-0294. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

**CLF** 

PONNATHAPU ACHUTAMURTHY SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600